Sanofi India Board Proposes ₹48 Dividend, Plans Director Appointment

Sanofi India's Board has proposed a final dividend of ₹48 per share for fiscal year 2025. In addition, the board backed the appointment of Siraj Azmat Chaudhry as an Additional Independent Director for a five-year term starting April 1, 2026. Shareholder approval is required for the director role at the upcoming Annual General Meeting (AGM).

Board Meeting Decisions

The board convened on March 25, 2026, greenlighting the ₹48 per share final dividend for the year ended December 31, 2025. It also approved Mr. Chaudhry's nomination as an Additional Independent Director, a role he would hold for five years from April 1, 2026. Shareholders will vote on his appointment at the 70th AGM on April 29, 2026.

Impact for Shareholders and Board

The recommended dividend offers a direct reward to Sanofi India's investors for 2025 performance. Mr. Chaudhry's proposed addition aims to strengthen the board's oversight and bring fresh expertise to the company's strategic direction.

Company Context and Recent Challenges

Sanofi India, part of the global Sanofi group since 1956, has a track record of shareholder payouts. Recently, the company has also been planning to spin off its consumer healthcare business. However, it has faced challenges, including historically slow sales growth over the past five years. In February 2026, the All India Chemists and Distributors Federation (AICDF) filed a complaint regarding trade policies, raising concerns about potential regulatory issues.

Key Changes for Investors

Investors can anticipate a ₹48 per share dividend for FY2025 if approved. The board's composition may be enhanced by Mr. Chaudhry's experience. The upcoming AGM on April 29, 2026, is a key date for shareholder participation.

Potential Hurdles Ahead

Mr. Chaudhry's directorship hinges on shareholder approval at the AGM. The company's past five years of sluggish sales growth remain a point of investor focus. The AICDF complaint signals potential friction with trade partners, which could affect distribution or attract regulatory attention.

Competitive Landscape

Operating in India's competitive pharmaceutical sector against rivals like Sun Pharma, Cipla, and Dr. Reddy's, Sanofi India shows strong management risk oversight. However, its one-year returns have lagged some peers, and its five-year sales growth has been notably weak.

Looking Ahead

Investors will be watching the shareholder vote at the 70th AGM concerning Mr. Chaudhry's appointment. The timing and processing of the final dividend payout are also key. Sanofi India's efforts to boost sales growth and resolve trade partner issues will be closely monitored, alongside progress on the consumer healthcare demerger.